ROCHE HOLDING AG
Fluid (Atrophied T2 Lesion Volume)
in Primary-Progressive Multiple
Sclerosis: Results from the Phase
III ORATORIO Study
----------------------- ---------------------------------------------- -------------------------------
Recently Diagnosed Early-Stage P15.099
RRMS: NEDA, ARR, Disability Progression, P15: MS Clinical Trials
Serum Neurofilament and Safety: and Therapeutics
1-Year Interim Data from the Ocrelizumab
Phase IIIb ENSEMBLE Study
---------------------------------------------- -------------------------------
Adherence and Persistence to Disease-modifying P15.228
Therapies for Multiple Sclerosis P15: MS Health Care
and Their Impact on Clinical and System/Policy Based
Economic Outcomes in a U.S. Claims Research
Database
---------------------------------------------- -------------------------------
Safety of Ocrelizumab in Multiple P15.203
Sclerosis: Updated Analysis in P15: MS Therapeutics
Patients with Relapsing and Primary MOA and Safety
Progressive Multiple Sclerosis
----------------------- ---------------------------------------------- -------------------------------
Fenebrutinib The Safety of Fenebrutinib in a S25.005 (oral presentation)
for Multiple Large Population of Patients with S25: MS and CNS Inflammatory
Sclerosis Diverse Autoimmune Indications Disease: Emerging Therapeutics
Supports Investigation in Multiple and Biomarkers
Sclerosis (MS) Tuesday, April 20 at
4:40 pm ET
----------------------- ---------------------------------------------- -------------------------------
Fenebrutinib Demonstrates the Highest P15.091
Potency of Bruton Tyrosine Kinase P15: MS Clinical Trials
Inhibitors (BTKis) in Phase 3 Clinical and Therapeutics
Development for Multiple Sclerosis
(MS)
----------------------- ---------------------------------------------- -------------------------------
ENSPRYNG (satralizumab) Satralizumab in Patients with Neuromyelitis P2.019
for Neuromyelitis Optica Spectrum Disorder and Concomitant P2: Autoimmune Neurology:
Optica Spectrum Autoimmune Disease Advances in Neuromyelitis
Disorder Optica Spectrum Disorder
(NMOSD)
----------------------- ---------------------------------------------- -------------------------------
Neuromyelitis Disease Phenotype Correlates with P2.091
Optica Spectrum Treatment Change in NMOSD Patients P2: Autoimmune Neurology:
Disorder of the CIRCLES Cohort Clinical Observations
and Advances
----------------------- ---------------------------------------------- -------------------------------
Demographic and Relapse Correlates P2.013
of Treatment Change in NMOSD Patients: P2: Autoimmune Neurology:
Analysis of the CIRCLES Study Advances in Neuromyelitis
Optica Spectrum Disorder
(NMOSD)
----------------------- ---------------------------------------------- -------------------------------
Relapse Profile Correlates with P2.012
Treatment Change in NMOSD Patients P2: Autoimmune Neurology:
of the CIRCLES Cohort Advances in Neuromyelitis
Optica Spectrum Disorder
(NMOSD)
---------------------------------------------- -------------------------------
Correlates of Rituximab Discontinuation P2.014
in Patients with NMOSD: a CIRCLES P2: Autoimmune Neurology:
Cohort Analysis Advances in Neuromyelitis
Optica Spectrum Disorder
(NMOSD)
----------------------- ---------------------------------------------- -------------------------------
Alzheimer's Linking Amyloid to Cognition in P1.052
Disease the Pathogenesis and Treatment P1: Aging and Dementia:
of Alzheimer's Disease: Toward Biomarkers
the Development of a "Quantitative
A/T/N Model"
----------------------- ---------------------------------------------- -------------------------------
Gantenerumab Utilization of Home Nursing to P1.014
for Alzheimer's Mitigate the Impact of COVID-19 P1: Aging and Dementia:
Disease on the Conduct of the Gantenerumab Clinical Trials
GRADUATE Trials
----------------------- ---------------------------------------------- -------------------------------
Semorinemab A Disease Progression Model for P1.061
for Alzheimer's Alzheimer's Disease Predicts Longitudinal P1: Aging and Dementia:
Disease Trajectory of CDR-SB Score Across Neuropsychology
Different Stages of the Disease
----------------------- ---------------------------------------------- -------------------------------
Huntington's Burden of Illness among U.S. Medicare P14.043
Disease Beneficiaries with Late-onset Huntington's P14: Huntington's Disease
Disease
----------------------- ---------------------------------------------- -------------------------------
Clinical Characteristics of Late-Onset P14.046
Huntington's Disease in North Americans P14: Huntington's Disease
from the Enroll-HD Study
----------------------- ---------------------------------------------- -------------------------------
Clustering and Prediction of Disease P14.147
Progression Trajectories in Huntington's P14: Clinical Trials,
Disease: An Analysis of the Enroll-HD Surveys, and Studies
and REGISTRY Database Using a Machine in Movement Disorders
Learning Approach
----------------------- ---------------------------------------------- -------------------------------
About EVRYSDI(TM) (risdiplam)
EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier
designed to treat SMA by increasing production of the survival of motor
neuron (SMN) protein. SMN protein is found throughout the body and is
critical for maintaining healthy motor neurons and movement. EVRYSDI is
administered daily at home in liquid form by mouth or by feeding tube.
The U.S. Food and Drug Administration (FDA) approved EVRYSDI for the
treatment of SMA in adults and children 2 months of age and older.
EVRYSDI was granted PRIME designation by the European Medicines Agency
(EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and
2019, respectively. At this time, EVRYSDI has been approved in 38
countries and submitted in a further 33 countries.
About OCREVUS(R) (ocrelizumab)
OCREVUS is the first and only therapy approved for both RMS (including
clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and
PPMS, with dosing every six months. OCREVUS is a humanised monoclonal
antibody designed to target CD20-positive B cells, a specific type of
immune cell thought to be a key contributor to myelin (nerve cell
insulation and support) and axonal (nerve cell) damage. This nerve cell
damage can lead to disability in people with MS. Based on preclinical
studies, OCREVUS binds to CD20 cell surface proteins expressed on
certain B cells, but not on stem cells or plasma cells, suggesting that
important functions of the immune system may be preserved.
OCREVUS is administered by intravenous infusion every six months. The
initial dose is given as two 300 mg infusions given two weeks apart.
Subsequent doses are given as single 600 mg infusions. With rapidly
growing real-world experience and more than 200,000 people treated
globally, OCREVUS is the first and only therapy approved for relapsing
MS (RMS; including RRMS and active, or relapsing, secondary progressive (MORE TO FOLLOW) Dow Jones Newswires
April 08, 2021 01:00 ET (05:00 GMT)
